These data indicate that EGFR signaling contributes to the IFNγ- and PD-L1-dependent immunosuppressive response and suggest that ALIX integrates the signaling of two important regulators of tumor-mediated immunosuppression, modulating PD-L1 surface expression and the EGFR signaling required for the associated immunosuppressive phenotype. The gene discussed is EGFR; the disease is neoplasm.